TSX: MDNAOTCQB: MDNAF
©2018 Medicenna. All Rights Reserved.
Q3 2019
Forward-Looking Statements
Q3 2019 Medicenna Corporate Overview
Certain statements in this presentation are “forward-looking statements. Any statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words
or phrases such as “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results
may, could, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”.
Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks
and uncertainties which would cause actual results or events to differ materially from those presently anticipated. Forward-looking statements are
based on expectations, estimates and projections at the time the statements are made and involve significant known and unknown risks, uncertainties
and assumptions. A number of factors could cause actual results, performance or achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by such forward-looking statements. These include, but are not limited to, the risk
factors discussed in the public filings made by Medicenna with the applicable securities commissions in Canada, including the Annual Information
Form dated June 24, 2019. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking
statements contained in this document. These factors should be considered carefully and prospective investors should not place undue reliance on
these forward-looking statements.
Although the forward-looking statements contained in this document are based upon what Medicenna currently believes to be reasonable assumptions,
Medicenna cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking
statements. Except as required by law, Medicenna does not have any obligation to advise any person if it becomes aware of any inaccuracy in or
omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to
reflect new events or circumstances.
2
Q3 2019 3
MDNA55 — LEAD PROGRAM SUPERKINE PLATFORM CORPORATE SNAPSHOT
TARGETS IL4R: EXPRESSED IN GBMCompelling Clinical Data in 112 rGBM
Patients
ORPHAN/FAST TRACK Orphan Drug (FDA, EMA)
Fast Track (FDA)
IL-2; IL-4; IL-13Tunable cytokines
MULTIPLE NEAR TERM MILESTONES
PHASE 2B TRIAL ENROLMENT COMPLETED
4,000Brain tumor patients can be treated with 1 gram
of MDNA55
MDNA109: BEST IN CLASS IL-2 SUPER-
AGONIST
WORLD CLASS EXPERTISE
Clinical and scientific advisors, collaborators and inventors
250,000Annual incidence
of GBM and metastatic brain cancer2
$2 BILLIONPotential market of MDNA55 market for brain cancer ($US)1,3
EXCEPTIONAL CD122 SELECTIVITY
Boosts cancer killing immune cells
13 PATENT FAMILIESStrong technology platform protection
1. BioXcel Strategic Analysis Report, 2014.2. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012.3. Decision Resources, Inc Glioblastoma Report, Sept 2013.
Medicenna Corporate Overview
4
Multiple Near-Term Value Inflection Milestones
Q3 2019 Medicenna Corporate Overview
MDNA55• Completed enrollment in Phase 2b rGBM trial• Reported promising rGBM Phase 2b preliminary top-line results• End of Phase 2 meeting with FDA• Commence Phase 2a clinical trial in newly diagnosed glioblastoma
MDNA109• Select lead candidate with extended half life• Complete dose range finding studies for pre-IND meeting with FDA• Complete IND enabling studies in preparation for Phase 1 clinical trial
Phase 2 clinical results for MDNA55
in rGBM
MDNA109 to be IND Ready
5
Financial Snapshot
Q3 2019 Medicenna Corporate Overview
• Funding to date: CDN$20 M + Up to US$14.1M Non-Dilutive CPRIT Grant
• Cash and cash receivable balance at March 31, 2019: CDN$4.8 million
• Available to be drawn under CPRIT grant: Up to US$2.3 million
• Total available cash excluding warrant exercises: Up to CDN$7.5 million
• No Debt, No Preferred Shares
Issued and Outstanding28,802,792
Fully Diluted37,048,220
TSX: MDNAOTCQB: MDNAF
MDNA55A Powerful Molecular Trojan Horse Targeting Glioblastoma
MDNA55: A Powerful Molecular Trojan Horse
7
Targeteddelivery of toxin
Tumor Targeting Domain
Circularly Permuted Interleukin-4 (cpIL-4)
ENDOCYTOSIS
FURIN PROTEASEADP RIBOSYLATION
Inhibit Protein Synthesis
CELL DEATH
NUCLEUS
Tumor Killing “Cytotoxic” DomainCatalytic domain of Pseudomonas Exotoxin A (PE)
• Bypass the BBB via convection enhanced delivery (CED)
• Potently toxic to tumor cells
• Simultaneously purges the tumor microenvironment (TME)
Q3 2019 Medicenna Corporate Overview
> 300 Patient Biopsies Analyzed Show IL-4R Over-Expression1-7
8
Targeting the IL-4 Receptor in Brain Tumors
Glioblastoma
76%Mixed Adult
Glioma
>83%Mixed Pediatric
Glioma
76%Pediatric DIPG
71%
Medulloblastoma
100%Adult Pituitary
Adenoma
100%Meningioma
77%Normal Brain
Tissue
0%1. Joshi BH, et. al. Cancer Res 2001;61:8058-8061.2. Puri RK, et. al., Cancer Res 1996;56:5631-5637. 3. Kawakami M, et. al., Cancer. 2004 Sep 1; 101(5):1036-42. 4. Berlow NE, et al. PLoS One. 2018 Apr 5; 13(4):e0193565.
5. Joshi BH, et. al. British J of Cancer (2002) 86, 285 –291.6. Chen L, et al. Neurosci Lett. 2007 Apr 24; 417 (1):30-5.7. Puri S, et. al., Cancer. 2005 May 15; 103(10):2132-42.
Q3 2019 Medicenna Corporate Overview
IL4R Predicts Poor Survival in GBM
9
Kohanbash G et al. Cancer Res 2013;73:6413-6423
IL4R +/+ (n=10); symptom-free survival = 55.5 daysSymptom-free survival = 90 daysIL4R -/- (n=15); symptom-free survival = 90 days
Survival in Subjects with GBM
-- No expression of IL-13Rα1 (n=32): mOS = 693 days-- High expression of IL-13Rα1 (n=65): mOS = 350 days
Survival in Glioma Mouse Model
Han J. and Puri R. J of Neuro-Oncology (2018) 136:463–474
Expression of IL-13Rα1 mRNA positively correlates with IL-4Rα indicating that these two receptors may form a complex in GBM.
Medicenna Corporate OverviewQ3 2019
10
TME-Infiltrating MDSCs Express IL4R and Predict Poor Survival in GBM
MDSC gene signature (based on the combined positive expression of CD11b,
CD33, CD45, CD244, and CXCR2) negatively correlates with GBM patient
prognosis. Statistical significance of survival was based on log-rank analysis.
Otvos B et. al., (2016). Stem Cells 34:2026–2039Surface expression of IL-4Ra on tumor-infiltrating and splenic CD11b+/Gr-1+
MDSCs from GL26 tumor-bearing mice.
TME-MDSCs show 12-fold increase in IL-4R⍺expression compared to splenic myeloid cells
p < 0.001
Kamran N, et. al., (2017). Mol Ther 25:232-248
Medicenna Corporate OverviewQ3 2019
MDNA55 Treatment
Direct infusion into tumor
convection enhanceddelivery (CED)
75%
INOPERABLE rGBM
11
Treatment Pathway for GBM
* Expression of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is responsible for resistance to Temodar used in GBM treatment.
DIAGNOSISADJUVANT TEMODARSURGERY
(85-90%) 55% of GBM Temodar-Resistant*
RADIOTHERAPY TEMODAR
RELAPSE
25%
OPERABLE rGBM
GBM IS UNIFORMLY FATAL – VIRTUALLY ALL TUMORS WILL RECUR (rGBM)
MDNA55 treatment can also provide benefit in newly diagnosed and
operable rGBM settings
Q3 2019 Medicenna Corporate Overview
Convection-Enhanced Delivery (CED)
Bypassing the BBB with Image-Guided Direct Drug Delivery
12
Treatment duration of 1 day
Image-guidedcatheter placement
Catheters prevent backflow
Real-time monitoring ensures tumor coverage
Q3 2019 Medicenna Corporate Overview
Open-Label Single Arm Study in Recurrent GBM Patients (NCT02858895)
13
MDNA55-05 Phase 2b Study Design Summary
DIAGNOSIS PLANNING TREATMENT FOLLOW UP
Q3 2019 Medicenna Corporate Overview
14
Promising Survival of MDNA55 Compared to Approved Therapies for rGBM
Monotherapy Population (n) SurvivalmOS (mos.)
MDNA55-05 Low Dose(median 63 µg) rGBM (n=21) 11.8
Avastin1 rGBM (n=85) 9.2
Avastin2 rGBM (n=50) 8.0
Lomustine2 rGBM (n=46) 8.0
Temozolomide3 rGBM (n=31) 5.6
Temozolomide4 rGBM (n= 792) NA
MDNA55-05 High Dose Cohort(median 180 µg)
Enrolment completed; currently collecting survival data
1 Friedman et al., Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.2 Taal et al, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomisedcontrolled phase 2 trial. Lancet Oncol 2014 Aug;15(9):943-533 Kim et al., Outcome of salvage treatment for recurrent glioblastoma. J Clin Neuroscience 22 (2015) 468–473, 2015.4 Chen et al., The efficacy of temozolomide for recurrent glioblastoma multiforme (Meta-analysis). Eur J Neurol, 2013 Feb; 20(2):223-30.
Medicenna Corporate OverviewQ3 2019
0 100 200 300 400 500 600 700 8000
50
100
Days elapsed
Perc
ent s
urvi
val
IL4R+ (H-Score > 75); n=8
IL4R- (H-Score ≤ 75); n=10
Log-Rank Test p-value = 0.0147
IL4RHigh (H-Score > 75); n=8
IL4RLow (H-Score ≤ 75); n=10
Time Since MDNA55 Treament (Days)
IL4R+ve is Associated with Longer Survival Following MDNA55 Treatment
15
IL-4R Status
mOS(months) OS-6 OS-9 OS-12
IL4R+ve 15.2 100% 88% 60%
IL4R-ve 8.1 70% 30% 20%
IL4R+ve (H-Score > 75); n=8
IL4R-ve (H-Score ≤ 75); n=10
Medicenna Corporate OverviewQ3 2019
16
Pseudo-Progression in GBM Following Immunotherapy
https://www.immunooncologyhcp.bmsinformation.com/clinical-expectations/pseudo-progression
Medicenna Corporate OverviewQ3 2019
Immunotherapy Response Assessment in Neuro-Oncology (iRANO)
17
Patient classified as PD
Duration on Immunotherapy Regimen
> 6 months ≤ 6 months
Continue on study as long as no significant clinical decline
Repeat imaging after initial imaging progression and compare to the new reference scan (Nadir)
CR, PR, or SD Confirms PD
Chukwueke UN et al., CNS Oncol. 2019 Mar 1;8(1):CNS28
(CR): 100% volume decrease(PR): ≥ 65% volume decrease(SD): < 65% volume decrease to
< 40% volume increase(PD): ≥ 40% volume increase
Medicenna Corporate OverviewQ3 2019
Tumor response or stabilization seen in 14 of 19 evaluable subjects = Disease control rate of 74%
18
Disease Control Seen from Nadir in Low Dose Cohort
IL4R PositiveIL4R NegativeNo IL4R data available
Medicenna Corporate OverviewQ3 2019
Longer Survival is Associated with Stable Disease or Better
19
ResponseStatus
mOS(months)
SD or better 13.7PD 8.5
p-value 0.0635
0 200 400 600 8000
50
100
Best Response from Nadir (Survival)
Days Since MDNA55 Treatment
Per
cent
sur
viva
l
Progressive Disease (n=5)
Stable Disease or Better (n=14)
Medicenna Corporate OverviewQ3 2019
Tumor response or stabilization seen in 21 of 23 evaluable subjects = Disease control rate of 91%
20
Disease Control Seen from Nadir in High Dose Cohort
IL4R PositiveIL4R NegativeNo IL4R data available
Medicenna Corporate OverviewQ3 2019
Tumor response or stabilization seen in 35 of 42 evaluable subjects = Disease control rate of 83%
21
Disease Control Seen with MDNA55 from Nadir
IL4R PositiveIL4R NegativeNo IL4R data available
Medicenna Corporate OverviewQ3 2019
MDNA55 Brain Cancer Market Opportunity
Tumor Type Annual Incidence1 Projected Market2
Recurrent Glioblastoma (rGBM) 33,300 $650M
Metastatic Brain Cancer3 91,500 $1.30B
Pediatric Glioma 3,800 $50M
Total 133,500 $2.0B
22
1. GLOBOCAN 2012 http://globocan.iarc.fr/Default.aspx2. U.S., Europe and Japan3. Metastatic Brain Cancer numbers from colon, breast and kidney cancer only
Market Size Estimated at $2B Annually
Q3 2019 Medicenna Corporate Overview
>2000 Patient Biopsies Analyzed Consistently Show IL4R Over-Expression
23
Future Opportunity: 1 Million IL4R Cancers Annually
Glioblastoma
76%
Bladder
73%Breast
82%Colorectal
89%Head and Neck
75%
NSCLC
79%Mesothelioma
96%Ovarian
60%Pancreatic
60%
Medicenna Corporate OverviewQ3 2019
MDNA109: IL-2Super Agonist for Cancer Immunotherapy
Proleukin (hIL-2): first targeted immunotherapy
25
Rationale for an IL-2 Superkine Agonist (MDNA109)
• Proleukin is approved for skin and renal cancer
• High-dose Proleukin is required to stimulate effector cells
• IL-2 preferentially stimulates the high-affinity receptor, causing:
• Activation of Tregs; Tregs abrogate anti-tumor responses
• Extreme toxicity – hard to complete full course of therapy
• Treatment in Intensive Care Unit
Has very high affinity for IL-2
High-affinity receptor
IL-2
(CD25)
(CD122)
(CD132)
Medicenna Corporate OverviewQ3 2019
MDNA109: 200-fold Higher Affinity for CD122 (IL-2Rβ) Than Native IL-2
26
• Mutations in the core of IL-2 improves
affinity to CD122 on CD8 T cells and NK
cells
• CD122 affinity is key for the activation of
immune cells responsible for cancer killing
(CD8+ T cells, naïve T cells, NK cells,…)
IL-2Rβ binding site
Helix C
Helix A
Helix B
Helix D
Levin, Bates, and Ring et. al, Nature, 2012
SPR data (nM) CD25 CD122
IL-2 6.6 280
MDNA109 6.6 1.4
Similar affinity to
CD25
200 X increase affinity to
CD122
Medicenna Corporate OverviewQ3 2019
Stimulation of Intermediate Affinity Receptor Required for Anti-Tumor Effect
27
Rationale for an IL-2 Superkine Agonist (MDNA109)
• IL-2 Superkine (MDNA109) signals via the intermediate affinity receptor
• Preferentially activates effector T cells that attack tumor cells (naïve T cells, NK cells, and CD8 T cells)
• Mediates anti-tumor effect
• Derive therapeutic benefits without the underlying toxicity
Weak Signaling
Intermediate affinity receptor
IL2 MDNA109
Signaling
(CD122)(CD132)
(CD122)(CD132)
Medicenna Corporate OverviewQ3 2019
MDNA109 More Potent and Less Toxic then Wild-type IL-2
28
Levin, Bates, and Ring et. al, Nature, 2012
Reduced Adverse Effects in Vivo
Selective Expansion of CD8+ T Cells in Vivo
10
5
0
15
Cel
ls p
er s
plee
n (x
106 )
PBSIL-2
MDNA109
PBSIL-2 MDNA109
0.20
0.15
0.10
0.25Pu
lmon
ary
wet
wei
ght (
g) 0.30
PBS IL-2
MDNA109
Anti-tumor response against pulmonary B16F10 nodules. B6 mice received 3x 105 B16F10 cells intravenously, followed by five daily injections of either PBS, 20 μg IL-2, or 20 μg MDNA109, starting three days after tumor injection. Shown are photographs of fixed whole lungs on day 16 after tumor injection.
CD8+Treg
Medicenna Corporate OverviewQ3 2019
5 10 15 20 25 30 35 40 450
500
1000
1500
2000
Days Post-Implant
Mea
n Tu
mor
Vol
ume
(mm
3 )
PBSanti-PD-1MDNA109 (5 ug q.d.)MDNA109 (25 ug q.d.)anti-PD-1 + MDNA109 (5 ug q.d.)anti-PD-1 + MDNA109 (25 ug q.d.)
9/10 cures
1/10 cures
0/10 cures
29
MDNA109 Synergizes with Anti-PD-1 Immunotherapy
C57BL/6 mice were implanted with 106 MC38 murine colon tumor cells
subcutaneously above hind limb. When tumor reached approximately 125mm3,
animals were randomized into groups and dosing was initiated by intraperitoneal
injections; q.d. = daily. **p=0.01; ***p=0.001
**
**
**
***
Combination Therapy Produces Robust Dose-Dependent Responses in MC38 Colon Cancer Model
• MDNA109 and anti-PD-1 are not
fully efficacious alone
• Dose-dependence observed with
monotherapy and anti-PD-1
• Combination treatment sufficient to
cure most mice
• Increased efficacy of combination
was well-tolerated
Medicenna Corporate OverviewQ3 2019
0 20 40 60 80 100 1200
500
1000
1500
2000
2500
Study Day
Tum
or v
olum
e (m
m3 )
30
TxStart
***
****
****
MDNA109 Synergizes with Anti-CTLA-4 Immunotherapy
MDNA109 (1mg/kg) and IL2 (1mg/kg) administered IP daily x5 for 2 cycles; anti-CTLA4 (200 µg) administered IP twice weekly for two cycles; average tumor volume at treatment start was 18 mm3; asterisks indicate significant differences as compared to Isotype control group (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).
Combination Therapy Produces Robust Tumor Responses in CT26 Colon Cancer Model
• MDNA109 and anti-CTLA4 are not fully efficacious alone
• Dramatically superior response when compared to IL-2 combination
• MDNA109 combination with anti-CTLA4 is sufficient to cure most mice
• MDNA109 can synergize with checkpoint inhibition to fully unleash the immune system against cancer
Medicenna Corporate OverviewQ3 2019
40 50 60 70 80 90 1000
500
1000
1500
Days Post Implant
Tum
or v
olum
e (m
m3 )
Secondary Challenge
TertiaryChallenge
MDNA109-LA + Anti-CTLA4 (n=8)
MDNA109-LA Synergizes with Anti-CTLA4 Immunotherapy
31
8 CR (100%)
Vehicle (n=9)
0 10 20 30 40 50 60 70 80 90 1000
500
1000
1500
2000
Days Post Implant
Tum
or V
olum
e (m
m3 )
Dose
Anti-CTLA4 (n=9)
0 10 20 30 40 50 60 70 80 90 1000
500
1000
1500
2000
Days Post Implant
Tum
or V
olum
e (m
m3 ) Dose
MDNA109-LA (n=9)
0 10 20 30 40 50 60 70 80 90 1000
500
1000
1500
2000
Days Post Implant
Tum
or V
olum
e (m
m3 )
Dose
MDNA109-LA+ Anti-CTLA4 (n=9)
0 10 20 30 40 50 60 70 80 90 1000
500
1000
1500
2000
Days Post Implant
Tum
or V
olum
e (m
m3 )
Dose
6 CR (67%)2 PR (22%)
6 CR (75%)
1
2
Primary CT26 tumor challenge
3
Secondary challenge with
2x106 CT26 cells re-injected into
left flank
2
Tertiary challenge with
2x106 CT26 cells re-injected into
right flank
Medicenna Corporate OverviewQ3 2019
MDNA109-LA + Anti-CTLA-4 Immunotherapy Improves Survival
32
Survival Curve
0 20 40 60 80 1000
25
50
75
100
Days Post Implant
Per
cent
sur
viva
l
Medicenna Corporate OverviewQ3 2019
MDNA109-LA1: Does not Bind to CD25 (IL-2⍺)
33
Surface Plasmon Resonance (SPR) Assay
Medicenna Corporate OverviewQ3 2019
MDNA109-LA1 Selectively Activates CD8 T Cells vs. Tregs
34
STAT5 Phosphorylation Assay Using Human PBMCs
0.01 0.1 1 10 100 1000 10000 1000000
20
40
60
80
100
Tregs
Conc (pM)
pSTA
T5+
(%)
IL2LAMDNA109LAMDNA109LA1
1 10 100 1000 10000 1000000
20
40
60
80
100
Conc (pM)
pSTA
T5+
(%)
CD8+ CD25-
IL2LA
MDNA109LA1MDNA109LA
IL2L
A
MDNA109L
A
MDNA109L
A11
10
100
1000
10000
CD
8/Tr
eg E
C50
rat
io
5,800
170
3
Medicenna Corporate OverviewQ3 2019
8 10 12 14 16 18 200
250
500
750
1000
1250
Days Post Implant
Tum
or V
olum
e (m
m3 )
0 2 4 6 8 10 12 14 16 18 20 220
500
1000
1500
2000
2500
3000
3500
Days Post Implant
Tum
or v
olum
e (m
m3 )
MDNA109-LA1: Similar In Vivo Potency But Superior PK Profile
35
Treatment Start
Treatment Start
MDNA109-LA1 enables effective B16F10 tumor control with a once weekly schedule.
MDNA109-LA enables effective B16F10 tumor control with a biweekly schedule, a similar schedule as anti-PD-1 antibodies used in mice.
Medicenna Corporate OverviewQ3 2019
MDNA109 Variants are Not Immunogenic
36
Immunogenicity Assessment using the Epibase™ in silico T-cell epitope screening platform to predict
whether peptides derived from a given protein of interest bind to the HLA class II histocompatibility antigen,
DRB1 beta chain. Scores are generated and compared to chicken ovalbumin protein (a xenoantigen known
to trigger a potent immune response) as a positive control.
Compound DRB1 Score Proleukin 310
MDNA109 213
MDNA109-LA 296
MDNA109-LA1 555
Chicken ovalbumin (pos control) 4404
Medicenna Corporate OverviewQ3 2019
37
MDNA109-LA1: A Best-in-Class Long Acting IL-2/IL-15 Cytokine for Cancer Immunotherapy
PRODUCT MANUFACTURINGCD122
POTENCYPROTEIN
VERSATILITYHALF-LIFE SAFETY IMMUNOGENICITY
Proleukin® Simple Low High Minutes Poor Low
NKTR-214 Complex Low Low Days Better than IL-2 Low
ALKS 4230 Simple Low Low Minutes toHours
Better than IL-2 N/A
Synthorins Complex Low Low Potentially Days N/A Potentially High
MDNA109-LA1 Simple High HighPotentially
DaysBetter than
IL-2Potentially Low
Medicenna Corporate OverviewQ3 2019
Q3 2019 38
MDNA55 — LEAD PROGRAM SUPERKINE PLATFORM CORPORATE SNAPSHOT
TARGETS IL4R: EXPRESSED IN GBMCompelling Clinical Data in 112 rGBM
Patients
ORPHAN/FAST TRACK Orphan Drug (FDA, EMA)
Fast Track (FDA)
IL-2; IL-4; IL-13Tunable cytokines
MULTIPLE NEAR TERM MILESTONES
PHASE 2B TRIAL ENROLMENT COMPLETED
4,000Brain tumor patients can be treated with 1 gram
of MDNA55
MDNA109: BEST IN CLASS IL-2 SUPER-
AGONIST
WORLD CLASS EXPERTISE
Clinical and scientific advisors, collaborators and inventors
250,000Annual incidence
of GBM and metastatic brain cancer2
$2 BILLIONPotential market of MDNA55 market for brain cancer ($US)1,3
EXCEPTIONAL CD122 SELECTIVITY
Boosts cancer killing immune cells
13 PATENT FAMILIESStrong technology platform protection
1. BioXcel Strategic Analysis Report, 2014.2. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012.3. Decision Resources, Inc Glioblastoma Report, Sept 2013.
Medicenna Corporate Overview
39
Multiple Near-Term Value Inflection Milestones
Q3 2019 Medicenna Corporate Overview
MDNA55• Completed enrollment in Phase 2b rGBM trial
• Reported promising rGBM Phase 2b preliminary top-line results
• End of Phase 2 meeting with FDA
• Commence Phase 2a clinical trial in newly diagnosed glioblastoma
MDNA109• Select lead candidate with extended half life
• Complete dose range finding studies for pre-IND meeting with FDA
• Complete IND enabling studies in preparation for Phase 1 clinical trial
Phase 2 clinical results for MDNA55
in rGBM
MDNA109 to be IND Ready
Thank You!Elizabeth WilliamsChief Financial Officer
www.medicenna.com
Fahar Merchant, PhDPresident & CEO
Supplementary Slides
KD (MDNA109LA1+CD25)=nobinding
KD (IL2LA+CD25)=0.7nM
KD (LAMDNA109+CD25)=2 nM
KD (MDNA109LA+CD25)=3nM
Long-Acting MDNA109 Does not Bind CD25
MDNA109-LA1 does not bind to CD25
THOR-707 does not bind CD25
NKTR-214 shows reduced affinity to CD25
Charych D. et al, PLOS ONE, 2017
Milla, M. et al, Abstract P417, SITC 2018
ILR⍺ (CD25) KD IL2 = 8.6 nMKD 1-PEG-IL2 = 190 nMKD 2-PEG-IL2 = 487 nM
KD = 1.7 nM
Q3 2019 Medicenna Corporate Overview 42
Long-Acting MDNA109 Retains Powerful CD122 Binding Compared to IL2
43
MDNA109-LA1 binds to CD122 with high affinity
THOR-707 shows reduced affinity to CD122
NKTR-214 shows reduced affinity to CD122
Charych D. et al, PLOS ONE, 2017
ILRβ (CD122)
Milla, M. et al, Abstract P417, SITC 2018
KD IL2 = 239 nMKD 1-PEG-IL2 = 1770 nMKD 2-PEG-IL2 = 3952 nM
KD = 360 nM
LA-MDNA109
MDNA109-LA1
MDNA109-LA2
MDNA109-LA
IL2-LA
Q3 2019 Medicenna Corporate Overview
Long-Acting MDNA109 Shows Superior Potency in PBMC Studies
44
THOR-707 increases EC50of both Tregs and CD8
0.01 0.1 1 10 100 1000 10000 1000000
20
40
60
80
100
CD4+ Tregs
Conc (pM)
pSTA
T5+
(%)
IL2-FcMDNA109FEAA-Fc
Protein EC50 (pM)
IL2-Fc 0.7678
MDNA109FEAA-Fc 241.4
Protein EC50 (pM)
IL2-Fc 2595
MDNA109FEAA-Fc 597
1 10 100 1000 10000 1000000
20
40
60
80
100
Conc (pM)
pSTA
T5+
(%)
CD8+ Teff
IL2-FcMDNA109FEAA-Fc
Long-Acting MDNA109 increases EC50 of Tregs but lowers EC50 of CD8 T cells
IL2-LAMDNA109-LA1
IL2-LAMDNA109-LA1
Milla, M. et al, Abstract P417, SITC 2018
Q3 2019 Medicenna Corporate Overview
Long-Acting MDNA109 Show Better Potency in Combination with ICI in CT26 Model
45
Charych, D. et al, Clin Cancer Res, 2016
Q3 2019 Medicenna Corporate Overview
Long-Acting MDNA109 Shows Better Survival in Combination with ICI in CT26 Model
46
MDNA109-LA + ICIOverall Survival (n=9)
0 20 40 60 80 1000
25
50
75
100
Days Post Implant
Per
cent
sur
viva
l
THOR-707 + ICIOverall Survival (n=14)
MDNA109-LA 2.5 mg/kg IP 2x/week
MDNA109-LA + Anti-CTLA4 IP 2x/week
H.C. Wainwright Global Life Sciences Conference, London, April 2019
Q3 2019 Medicenna Corporate Overview